Antibacterial activity of liposome-encapsulated antibiotics against Pseudomonas aeruginosa attached to the matrix of human dermis.
The present studies were undertaken to compare the antibacterial activity of liposome vesicles containing amikacin, ciprofloxacin or polymyxin B in the removal of P. aeruginosa organisms from microcolonies growing on sections of the matrix of human dermis. Encapsulation efficiency of antimicrobials inside cationic liposomes was 30% for amikacin, 50% for ciprofloxacin, and 100% for polymyxin B. The sections of dermis were colonized for 72 h with P. aeruginosa strains isolated from burn wounds. After that time, an intense growth of microorganisms on the dermis surface was observed. The sessile organisms were treated (with mild shaking) with solutions of either liposomal or free amikacin, ciprofloxacin, and polymyxin B for 1 h, and also with a mixture of liposomal or free ciprofloxacin and polymyxin B (1:1) for 20 min. After treatment with liposomal antimicrobials, the mean per cent of viable cells attached to the dermis was 48.7% for liposomal amikacin, 17.4% for liposomal ciprofloxacin, 19.1% for liposomal polymyxin B, and 3.6% for a mixture of liposomal ciprofloxacin and liposomal polymyxin B. Removal of P. aeruginosa from microcolonies growing on the dermal matrix was more effective when liposomal formulations were used compared to the free antibiotics. Therefore, cleansing of the contaminated matrix of human dermis with liposomal ciprofloxacin, liposomal polymyxin B or with the mixture of both liposomal antibiotics seems to increase the efficacy at the removal of attached bacterial cells.
Department of Microbiology and Epidemiology, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
E A
EA
Trafny
M
M
Antos-Bielska
J
J
Grzybowski
D000583:Amikacin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001422:Bacterial Adhesion / Q000187:drug effects; D002939:Ciprofloxacin / Q000008:administration & dosage; D020405:Dermis / Q000382:microbiology*; D004337:Drug Carriers; D005109:Extracellular Matrix / Q000382:microbiology; D006801:Humans; D008081:Liposomes; D011112:Polymyxin B / Q000008:administration & dosage; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity
D000900:Anti-Bacterial Agents; D004337:Drug Carriers; D008081:Liposomes; D002939:Ciprofloxacin; D000583:Amikacin; D011112:Polymyxin B